To view a copy of this licence, visit About this article Cite this article Godlewska, B.R., Sylvester, A.L., Emir, U.E
People receiving semaglutide, even at lower levels of weight loss, are achieving significant rates of improvement across a whole range of MASH parameters Professor Philip Newsome, Director of the Roger Williams Institute of Liver Studies and co-leader of the ESSENCE trial More than a weight loss drug The findings reveal twin benefits
Thank you, Laura, and the entire team, for making this journey a positive and successful experience
P., Theocharis, A
"The use of naltrexone in low doses beyond the approved indication of opioid addiction"
doi: 10.1038/nrm2330 57 KesselsMMSchwintzerLSchlobinskiDQualmannB